such as those produced by AstraZeneca and Johnson & Johnson, were working with a platform for vaccine candidates that had already been tested against other infectious diseases. By contrast, mRNA ...

AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

MRNA), Merck (NYSE:MRK), and AstraZeneca (AZN), according to a recent research note from Morgan Stanley. Last year, Moderna (NASDAQ:MRNA) made headlines with its individualized mRNA cancer vaccine ...

We’re using mRNA, which we think of as the software ... phase II that is being developed for heart disease by our partner AstraZeneca. Here, a protein called vascular endothelial growth factor ...

An incorrect picture of 'mRNA' COVID-19 vaccines being more effective than 'viral vector' COVID-19 vaccines was forming across APAC. We readied to overcome a threat to vaccine trust Earlier this year, ...

Moderna is advancing mRNA therapeutics for cardiometabolic disease, immuno-oncology, and rare diseases, among other indications. The company also has existing partnerships with AstraZeneca ...

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

Meanwhile, the PAHO has chosen Argentina and Brazil to create two development centres to increase the production of vaccines with messenger RNA (mRNA ... produces the AstraZeneca vaccine in ...

Vaxzevria, AstraZeneca's 'viral vector' COVID-19 vaccine, was battling perception issues, with stakeholders holding the misconception that mRNA COVID-19 vaccines were more effective in preventing the ...